CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities:
Net loss	$ (101,420)	$ (179,852)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	1,278	1,412
Amortization of notes and securities discounts and debt issuance costs	0	18
Stock-based compensation expense	74,725	82,567
Accretion, net of amortization	(2,142)	(35)
Net realized losses on investment securities	(19)	16
Gain on investment	0	(11,167)
Premium deficiency reserve	(6,948)	(54,952)
Changes in operating assets and liabilities:
Accrued retrospective premiums	18,324	155
Other receivables	6,960	(203)
Surety bonds and deposits	19,481	(2,143)
Prepaid expenses	2,901	(10,857)
Other assets	2,861	(7,529)
Healthcare receivables	19,341	(29,925)
Non-Insurance receivable	(8,697)	0
Operating lease right-of-use assets	157	1,513
Unpaid claims	(24,710)	20,763
Accounts payable and accrued expenses	7,474	1,979
Accrued salaries and benefits	(4,311)	(451)
Deferred revenue	113,537	0
Other liabilities	281	(989)
Performance year obligation	(9,666)	12,739
Non-Insurance payable	23,306	82,592
Operating lease liabilities	(508)	(1,864)
Net cash provided by (used in) operating activities	132,205	(96,213)
Cash flows from investing activities:
Purchases of short-term investments, available-for-sale, and held-to-maturity securities	(74,156)	(169,889)
Proceeds from sales of short-term investments and available-for-sale securities	60,436	5,881
Proceeds from maturities of short-term investments, available-for-sale, and held-to-maturity securities	90,997	290,455
Purchases of property and equipment	(605)	(331)
Acquisition of Character Biosciences, Inc. Series A preferred shares	0	(250)
Net cash provided by investing activities	76,672	125,866
Cash flows from financing activities:
Issuance of common stock, net of early exercise liability	1,118	894
Treasury stock acquired	(3,399)	(6,044)
Net cash used in financing activities	(2,281)	(5,150)
Net increase in cash, cash equivalents, and restricted cash	206,596	24,503
Cash, cash equivalents, and restricted cash, beginning of period	186,213	299,968
Cash, cash equivalents, and restricted cash, end of period	392,809	324,471
Reconciliation of cash and cash equivalents and restricted cash
Cash and cash equivalents	310,079	324,471
Restricted cash	82,730	0
Total cash, cash equivalents, and restricted cash	392,809	324,471
Supplemental disclosure of non-cash activities
Performance year receivable	(377,239)	(1,177,421)
Performance year obligation	377,239	1,177,421
Right-of-use assets obtained in exchange for lease liabilities	0	642
Recognition of equity method investments and preferred stock	0	8,644
Derecognition of noncontrolling interest	0	3,903
Conversion of Character Biosciences, Inc. convertible note to preferred stock	$ 0	$ 250